---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-023842"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:24:59.978288+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics Q1 net loss $11.2M; NORSE EIGHT underway, SPA agreed, $172M financing

## Summary
- Net loss for Q1 FY2024 was $11.2M ($0.04/sh), compared to $18.7M ($0.08/sh) in prior year.
- Cash and equivalents at Dec 31, 2023: $10.4M; private placements for up to $172M (subject to shareholder approval).
- FDA SPA agreed on NORSE EIGHT protocol; first subject dosed Jan 2024. Success would satisfy second clinical trial requirement from CRL.
- BLA resubmission for ONS-5010 expected by end of CY2024; EU MAA decision targeted first half 2024.
- Company working to resolve CMC comments from CRL; expects resolution before NORSE EIGHT completion.

## SEC filing metadata
- accession: 0001104659-24-023842
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465924023842/0001104659-24-023842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465924023842/tm246210d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-023842
- JSON: https://secwatch.observer/filing/0001104659-24-023842.json
- Plain text: https://secwatch.observer/filing/0001104659-24-023842.txt

## Key facts
- Earnings Releases
  Outlook Therapeutics, Inc. reported first fiscal quarter ended December 31, 2023 results: net income $11.2 million, EPS $0.04 per basic and diluted share.
  - Period: first fiscal quarter ended December 31, 2023
  - Net income: $11.2 million
  - EPS: $0.04 per basic and diluted share
  - Result: reported results
  source text: For the fiscal first quarter ended December 31, 2023, Outlook Therapeutics reported a net loss attributable to common stockholders of $11.2 million, or $0.04 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465924023842/0001104659-24-023842-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.